Roche, a Swiss biopharmaceutical and diagnostic company, agreed to acquire Good Therapeutics, a developer of protein therapeutics, for $250m. “We are excited to bring Good’s innovative PD-1-regulated IL-2 program into our existing oncology pipeline, which nicely complements our efforts on next-generation PD-1-targeted IL-2 therapeutics and our broader oncology strategy of providing cancer patients with innovative solutions and improving health outcomes. With our proven track record in cancer immunotherapy, we are well-positioned to leverage our deep discovery, development, clinical, and manufacturing capabilities and worldwide reach to potentially bring innovative products from this program to patients as fast as possible," James Sabry, Roche Global Head of Pharma Partnering.